Work Here?
Vedanta Biosciences
Work Here?
Develops microbiome-based therapies using bacteria
Vedanta Biosciences
Work Here?
Develops microbiome-based therapies using bacteria
About Vedanta Biosciences
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$364.5M
Headquarters
Cambridge, Massachusetts
Founded
2010
Overview
Vedanta Biosciences focuses on developing microbiome therapies using groups of beneficial bacteria known as bacterial consortia. These consortia can colonize the human intestine and have the potential to treat various diseases. The company utilizes a proprietary discovery platform to identify and assemble these bacteria into effective therapeutic teams. Unlike many competitors, Vedanta has achieved commercial-scale production of its drug candidates while adhering to strict FDA regulations for safety and quality. The goal of Vedanta Biosciences is to transform healthcare by providing new treatment options through its innovative approach to drug discovery.
Simplify's Take
What believers are saying
- Fast Track designation for VE303 accelerates regulatory approval process.
- Phase 3 RESTORATiVE303 study positions Vedanta as a market leader for rCDI.
- Recent $106.5M funding round strengthens financial position and growth potential.
What critics are saying
- Competition from Seres Therapeutics with FDA-approved C. difficile treatment.
- High production costs may impact profitability and market reach.
- Regulatory challenges due to unclear FDA guidelines for microbiome therapies.
What makes Vedanta Biosciences unique
- Vedanta uses defined bacterial consortia for consistent therapeutic outcomes.
- First to achieve commercial-scale CGMP production of bacterial consortia drugs.
- Proprietary platform identifies and assembles optimal bacterial consortia for therapies.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$364.5M
Above
Industry Average
Funded Over
4 Rounds
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↑ 0%2 year growth
↑ 2%VE303 is an orally administered, potential first-in-class live biotherapeutic product candidate being developed to prevent recurrence of Clostridioides difficile infection (CDI). CAMBRIDGE, MA, May 21, 2024 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study. VE303 is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection (rCDI). The RESTORATiVE303 trial is evaluating the efficacy and safety of VE303 in patients with rCDI and is intended to form the basis for a Biologics License Application (BLA) to be filed with the U.S. Food and Drug Administration
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study of VE303, which is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection (rCDI). The RESTORATiVE303 trial is evaluating the efficacy and safety of VE303 in patients with rCDI and is intended to form the basis for a Biologics License Application to be filed with the U.S. Food and Drug Administration. The full text of the announcement from Vedanta is as follows:. Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study. VE303 is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection (rCDI). The RESTORATiVE303 trial is evaluating the efficacy and safety of VE303 in patients with rCDI and is intended to form the basis for a Biologics License Application (BLA) to be filed with the U.S. Food and Drug Administration. “Initiation of the RESTORATiVE303 study represents a key clinical milestone for the VE303 program
Colorcon Ventures joins a prominent list of investors who also participated in Vedanta’s fundraising round, including AXA IM Alts, The AMR Ac
Premium Earlier, Vedanta had formed a joint venture with Taiwanese electronics manufacturing giant Foxconn which announced plans to invest $19.5 billion in setting up a semiconductor wafer fabrication plant.
Vedanta Biosciences is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Vedanta Biosciences
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$364.5M
Headquarters
Cambridge, Massachusetts
Founded
2010
Vedanta Biosciences is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today